BioNTech SE - ADR vs Unity Software Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Unity Software Inc trades at $31.79 (market cap $13.86B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Unity Software Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | U | |
|---|---|---|
Market Cap | $22.86B | $13.86B |
Sector | Health | Technology |
52-Week High | $119.34 | $49.47 |
52-Week Low | $83.89 | $17.13 |
Enterprise Value | $6.53B | $13.96B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Unity Software (U) trades at $30.68, down 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $36.50. Recent earnings show mixed results, with Q3 2025 beating expectations but subsequent quarters missing, while revenue remains stable around $1.8 billion. The company maintains strong gross margins of 62.79% but reports negative net income margins, reflecting ongoing profitability challenges amid strategic shifts toward AI and advertising.
The outlook for Unity hinges on its AI integration and cost management, offering upside if execution improves, but risks include persistent losses, high debt, and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →